Astellas Pharma (STU:YPH) Total Liabilities : €12,179 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Astellas Pharma Total Liabilities?

Astellas Pharma's Total Liabilities for the quarter that ended in Sep. 2024 was €12,179 Mil.

Astellas Pharma's quarterly Total Liabilities declined from Mar. 2024 (€12,119.50 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€12,179.36 Mil).

Astellas Pharma's annual Total Liabilities declined from Mar. 2022 (€6,677.96 Mil) to Mar. 2023 (€6,628.24 Mil) but then increased from Mar. 2023 (€6,628.24 Mil) to Mar. 2024 (€12,119.50 Mil).

Astellas Pharma Total Liabilities Historical Data

The historical data trend for Astellas Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Total Liabilities Chart

Astellas Pharma Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

8,624.08

6,858.48

6,677.96

6,628.24

12,119.50

Astellas Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															12,064.96	11,880.67	12,119.50	-	12,179.36

Astellas Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Astellas Pharma's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7895.328	+	(2749.451	+	1323.199
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	151.517)
	=	12,119

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	21920.074	-	9800.579
	=	12,119

Astellas Pharma's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	6891.118	+	(3909.203	+	1229.417
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	149.62)
	=	12,179

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	21821.534	-	9642.176
	=	12,179

Astellas Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALPMY:USA ALPMF:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines